TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02722759

Intervention type: OTHER
Group type: OTHER
Intervention: hemoglobin measurement
Study: NCT03198416

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: High-resolution pharyngeal manometry catheter
Description: The system is a widely-used tool in gastrointestinal medicine for high resolution mapping of pressures within tubular organs.The device will be deployed trans-nasally into the pharyngeal and esophageal lumen in exactly the same fashion as is done for motility studies.
Study: NCT01211223

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Administration of Metronidazole plus Amoxicillin
Description: Metronidazole plus Amoxicillin after, during and after root planning
Study: NCT01229527

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Patient receive a bolus of Remifentanil (0,5 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,5 mcg/Kg every time the patient presses its button.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil
Description: Patient receive a bolus of Remifentanil (0,8 mcg/Kg) before the procedure and the PCSA pump is set to inject further bolus doses of 0,8 mcg/Kg every time the patient presses its button.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meperidine
Description: Patient receive a bolus of Meperidine (0,7 mg/Kg) before the procedure and the PCSA pump with saline (sham PCSA) is connected.
Study: NCT04387422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental hyperglycemia
Description: Experimental hyperglycemia with MRI

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental hyperglycemia
Description: Experimental hyperglycemia with MRI
Study: NCT03202537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexlansoprazole
Description: dexlansoprazole treatment for Gastroesophageal Reflux symptoms
Study: NCT01498705

Intervention type: OTHER
Intervention: Procalcitonin level
Description: PCT level upon admission and on days 1, 3, and 5 following baseline level
Study: NCT04387422

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental hyperglycemia
Description: Experimental hyperglycemia with MRI
Study: NCT03670199

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dietary advice
Description: Nutritional status assessment Explanation of standard nutritional advices with an written explanation sheet

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Physiotherapist intervention
Description: Respiratory capacity Functional capacity

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dietary intervention
Description: Nutritional status assessment Presentation of the Nutrimus booklet by the coordinating dietitian Establishment or adaptation of a nutritional support (prescription of nutritional supplements if necessary). Delivery and explanation of the preoperative nutritional counseling support
Study: NCT03218319

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Renin measurement
Description: patients will have a blood sample for measuring renin activity
Study: NCT02380495

Intervention type: OTHER
Intervention: Data Collection

Intervention type: OTHER
Intervention: Data Collection
Study: NCT03332628

Intervention type: DEVICE
Group type: OTHER
Intervention: Microneedle patch
Description: Each patch contains 50 microneedles.
Study: NCT03546010

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Description: WISC test, BRIEF test, NEPSY-2 test, TAP2.3 test, Teach test

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Oculometric tests
Description: When the subject see a peripheric target, he should take a look not at the target but in the controlateral half-field, at a mirror position. This is called an anti-saccade task.
Study: NCT01821209

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Placement of sling
Description: Placement of a retropubic urethral sling will involve dissection and harvesting of the right and left vas deferens, which we will be taken out of the body by the bed side assistant who will suture the two vas deferens together in a side to side fashion with the smaller of the two vas deferens placed in the middle of the larger one. A single 3-0 V-lock suture on a CV23 needle will be placed through one end of the vas sling and then passed into the body by the bed side assistant. The sling will then be placed on the rectum below the site of the vesicourethral anastamosis and the anastamosis will be completed. The sling will then be placed around the vesicourethral anastomosis, suspended to the pubic symphysis and tensioned to allow elevation of the vesicourethral anastomosis.
Study: NCT00784550

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tiotropium Bromide
Description: Long-acting muscarinic antagonist

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol
Description: Inhaled corticosteroid plus long-acting bronchodilator
Study: NCT03926390

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bovine colostrum
Description: bovine colostrum for first 2 weeks
Study: NCT01637766

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan (intra-arterial infusion)
Description: Patients will undergo a minimally invasive procedure called spinal angiography. This procedure will identify the arteries feeding the tumor causing cord compression and will determine whether chemotherapy can be safely infused.~The chemotherapy will be infused via a tiny soft plastic tube (called microcatheter) at the tumor site over approximately 30 minutes.~The drug of choice is melphalan (trade name Alkeran) at a maximum dose of 16mg/m2, adjusted for white cell count, platelet count and renal function.~We will perform up to three intra-arterial chemotherapy treatments in 3-6 week intervals, based on the results of complete blood counts.
Study: NCT00648934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate Sprinkle Capsules 25 mg
Description: 25mg, single dose fed

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topamax® Sprinkle Capsules 25 mg
Description: 25mg, single dose fed
Study: NCT02865590

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sinus lift with Lyophilized Equine Bone Allograft (Bio-gen , Bioteck s.p.a., Arcugnano (VI) - Italy)

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sinus lift with deproteinized bovine bone allograft (Endobon Xenograft Granules, Zimmer Biomet, San Donato Milanese (MI) - Italy)
Study: NCT02387775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Esophageal temperature control
Description: Insertion of the Esophageal Cooling Device (ECD) will take place as described in the product monograph. The ECD will be connected to the heat exchange unit Blanketrol Hyper-Hypothermia System® (Cincinnati Sub-Zero, Cincinnati, OH) and will be used for temperature control for a total of 36 hours. A patient target of 35°C will be set on the heat exchange unit. Once target is attained, it will be maintained for 24 hours. Slow rewarming will then be achieved by increasing the input target by 0.2°C per hour, until a target of 36.6°C is reached.~All temperature data (device, input target, and patient bladder temperature) will be captured automatically using Data Export Software® (Cincinnati Sub-Zero, Cincinnati, OH) on an external laptop connected to the external heat exchange unit.
Study: NCT02466217

Intervention type: OTHER
Intervention: 1: AID groups
Description: Clinical and Biological investigations

Intervention type: OTHER
Intervention: 2: Control groups
Description: Clinical and Biological investigations
Study: NCT00779532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin
Description: Capsules containing 400 mg moxifloxacin, on Day 14 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2 (Org 10486-0 + Org 2317)
Description: Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2 (Org 10486-0 + Org 2317)
Description: Tablets containing 2.5 mg NOMAC and 1.5 mg E2, once daily dosing, orally taken. Daily dose either NOMAC-E2 2.5/1.5 mg or 12.5/7.5 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Moxifloxacin placebo
Description: Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Moxifloxacin placebo
Description: Moxifloxacin-placebo capsule taken orally, Day -1 and Day 14 only

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NOMAC-E2 placebo
Description: Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2 placebo
Description: Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NOMAC-E2 placebo
Description: Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NOMAC-E2 placebo
Description: Tablets containing NOMAC-E2 placebo, once daily dosing, orally taken.
Study: NCT02895646

Intervention type: OTHER
Intervention: Collection of blood sample

Intervention type: OTHER
Intervention: Collection of blood sample
Study: NCT03703908

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CCX140-B
Description: Orally administered tablet
Study: NCT01789580

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gambling moderator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gambling moderator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gambling moderator

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Gambling moderator
Study: NCT03309696

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and sham rTMS
Description: Both combinations of tDCS and rTMS in this intervention are sham.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and sham rTMS
Description: Both combinations of tDCS and rTMS in this intervention are sham.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and sham rTMS
Description: Both combinations of tDCS and rTMS in this intervention are sham.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and sham rTMS
Description: Both combinations of tDCS and rTMS in this intervention are sham.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and active rTMS
Description: tDCS in this intervention is sham and rTMS is active

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and active rTMS
Description: tDCS in this intervention is sham and rTMS is active

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and active rTMS
Description: tDCS in this intervention is sham and rTMS is active

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham tDCS and active rTMS
Description: tDCS in this intervention is sham and rTMS is active

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS and active rTMS
Description: Both combinations of tDCS and rTMS in this intervention are active

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS and active rTMS
Description: Both combinations of tDCS and rTMS in this intervention are active

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS and active rTMS
Description: Both combinations of tDCS and rTMS in this intervention are active

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active tDCS and active rTMS
Description: Both combinations of tDCS and rTMS in this intervention are active
Study: NCT06452745

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed as a regular practice during colorectal cancer screening.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed as a regular practice during colorectal cancer screening.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed as a regular practice during colorectal cancer screening.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed as a regular practice during colorectal cancer screening.

Intervention type: PROCEDURE
Intervention: Colonoscopy
Description: Colonoscopy performed as a regular practice during colorectal cancer screening.

Intervention type: OTHER
Intervention: Urine and FOBT collection
Description: After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.

Intervention type: OTHER
Intervention: Urine and FOBT collection
Description: After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.

Intervention type: OTHER
Intervention: Urine and FOBT collection
Description: After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.

Intervention type: OTHER
Intervention: Urine and FOBT collection
Description: After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.

Intervention type: OTHER
Intervention: Urine and FOBT collection
Description: After patients agreement, urine and FOBT are collected before the colonoscopy and before the diet preparation of the colon.
Study: NCT03670199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intensify physiotherapist intervention
Description: Respiratory capacity Functional capacity Tips adapted for physical activity and strengthening or maintenance of muscle mass Presentation of respiratory physiotherapy exercises to prevent postoperative bronchial congestion Nutrition and physical mobilization tips with the Nutrimus booklet
Study: NCT03209297

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMD treatment: physiotherapy and/or occlusal splints
Description: The patient will receive the most appropriate TMD treatment, based on current literature.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TMD treatment: physiotherapy and/or occlusal splints
Description: The patient will receive the most appropriate TMD treatment, based on current literature.
Study: NCT03945851

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: fMRI
Description: All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: fMRI
Description: All subjects will undergo 2 fMRI sessions. Each of these sessions will span two days, and subjects will spend 15 minutes in the MRI each day. fMRI tasks will consist of subjects grasping and releasing a handgrip. The control arm subjects will be offered a third fMRI session after unblinding and therapy with activation of the VNS.
Study: NCT00926302

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam (Lotus Pharmaceutical Co.,Ltd.)
Description: Levetiracetam 500mg/tablet Oral once

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Keppra (Levetiracetam - USB SA Pharma Sector)
Description: Levetiracetam 500mg/tablet oral once
Study: NCT04151771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Low-load blood flow restriction training
Description: The intervention group will perform the exercises of the lower limbs using LL-BFRT with an occlusion pressure of 70% of arterial occlusion pressure with low training loads (30% of the 1 repetition maximum).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual outpatient pulmonary rehabilitation
Description: The control group will perform outpatient pulmonary rehabilitation as established.
Study: NCT02998918

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: PolyResveratrol Supplementation
Description: Participants will take 1 mg of a polyresveratrol phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the polyresveratrol phytosome supplement on inflammation will be examined along with the short-term effect (1 week).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Curcumin Supplementation
Description: Participants will take 1 mg of a curcumin phytosome supplement each day for one week. The acute effect (1 hr) of one 500 mg dose of the curcumin phytosome supplement on inflammation will be examined along with the short-term effect (1 week).
Study: NCT03617458

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin is a drug has been on the market for several decades and is considered first line therapy for diabetes mellitus type 2.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A treatment with no active ingredients or therapeutic effect.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: A treatment with no active ingredients or therapeutic effect.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mHealth Intervention
Description: Our Health Insurance Portability and Accountability Act (HIPAA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: mHealth Intervention
Description: Our Health Insurance Portability and Accountability Act (HIPAA) compliant texting platform is linked to the Fitbit Application Program Interface. Real time activity data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.Subjects assigned to the texting arm will receive 3 texts/day in sync with their preferred morning, lunch, and evening leisure schedule, which is defined at enrollment. These texts will use personal, disease-specific, and provider information to deliver 2 types of messages customized to the current step count and sent in equal proportion. Messages are designed to facilitate self-awareness, reinforce step targets, and link physical activity with a reward or memorable cue.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Our HIPAA data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Our HIPAA data will be transmitted from the subject's smartphone to our mHealth platform via cellular network.
Study: NCT03642288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gastrografin
Description: Patients with CRE-induced SBO or ASBO both received GG challenge.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gastrografin
Description: Patients with CRE-induced SBO or ASBO both received GG challenge.
Study: NCT00273650

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: methylcobalamin
Description: Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: saline placebo
Description: Methylcobalamin (25,000μg/ml), at a dosage of 64.5μg/kg, or saline placebo administered subcutaneously, once every three days for six weeks. At six weeks, subjects cross over to the other treatment given every three days for another six weeks. Post 12 weeks, treatment with open label methylcobalamin will continue once every three days, for six months.
Study: NCT02617667

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: topical ocular, eye drops

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine A
Description: topical ocular, eye drops

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine A
Description: topical ocular, eye drops

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: topical ocular, eye drops
Study: NCT03074045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel (Kyleena, BAY86-5028)
Description: Low-dose LNG IUS with an initial in vitro release rate of 16 μg LNG/day, used continuously. The total LNG content in LCS16 is 19.5 mg. Administered intrauterine, for 12 months with an option for extended use for up to 5 years

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ethinyl estradiol and drospirenone (Yarina, BAY86-5131)
Description: COC tablet containing 30 μg ethinyl estradiol and 3 mg drospirenone (taken on cycle days 1-21, inclusive, followed by a 7-day tablet-free week) for 12 months
Study: NCT04685018

Intervention type: DEVICE
Intervention: fMRI acquisition
Description: Participants from the two groups will perform an avoidance-relief task inside an MRI scanner

Intervention type: DEVICE
Intervention: fMRI acquisition
Description: Participants from the two groups will perform an avoidance-relief task inside an MRI scanner